Press releases
- Evolus to Report Second Quarter Financial Results on July 31, 2024
- Evolus Announces Appointment of Albert G. White III to Board of Directors
- Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
- Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
- Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
- Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
- Evolus Reports First Quarter 2024 Results and Provides Business Update
More ▼
Key statistics
On Monday, Evolus Inc (0K16:LSE) closed at 12.06, -21.59% below its 52-week high of 15.38, set on Mar 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 12.06 |
Low | 12.06 |
Bid | -- |
Offer | -- |
Previous close | 12.06 |
Average volume | 332.00 |
---|---|
Shares outstanding | 62.61m |
Free float | 48.91m |
P/E (TTM) | -- |
Market cap | 770.74m USD |
EPS (TTM) | -1.05 USD |
Data delayed at least 20 minutes, as of Jul 22 2024 17:09 BST.
More ▼